Once daily solution achieves zero-to-trace cell severity

Article

Bromfenac ophthalmic solution 0.07% (Pro-Lensa, Bausch + Lomb) used once a day results in zero-to-trace (0–5 cells) cell severity in the anterior chamber following cataract surgery with implantation of a posterior chamber IOL, according to newly published research.

Bromfenac ophthalmic solution 0.07% (Pro-Lensa, Bausch + Lomb) used once a day results in zero-to-trace (0–5 cells) cell severity in the anterior chamber following cataract surgery with implantation of a posterior chamber IOL, according to newly published research. It also performed better than placebo in all outcome measures related to anterior chamber cell severity and inflammation, according to the US researchers, a group including representation from the drug’s manufacturer, Bausch + Lomb. They published their findings in Clinical Ophthalmology.

In two Phase III, double-masked, placebo-controlled, multicentre clinical trials, a total of 440 participants were randomly assigned to treatment with the bromfenac formulation or placebo. Participants were instructed to use once-daily dosing beginning one day before surgery, on the day of surgery and for 14 days after surgery. Follow-up occurred on days 1, 3, 8 and 15.

As early as the third day, researchers found, a significantly greater proportion of participants taking bromfenac had zero to five anterior chamber cells compared with the placebo group. This difference continued at day 8 and day 15, the latter day on which 80.2% of participants in the bromfenac and 47.2% of those in the placebo group met the criterion.

Overall anterior chamber cell scores and the summed ocular inflammation score were significantly lower in the bromfenac group compared with the placebo group at days 3, 8 and 15.

The authors note that, in April, based in part on the results of their clinical trial, the US Food and Drug Administration approved the formulation to treat postoperative inflammation and reduce ocular pain in those who have undergone cataract surgery. "In future clinical assessments, bromfenac 0.07% may be further evaluated in other ocular inflammatory disorders where [nonsteroidal anti-imflammatory drug] use may be potentially beneficial," they conclude.

To access the full study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.